Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 437, Issue 1, 2013, Pages 41-47

  Komatsu, Seiichiro ^a   Moriya, Shota ^a   Che, Xiao Fang ^a   Yokoyama, Tomohisa ^a,b   Kohno, Norio ^a   Miyazawa, Keisuke ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Kohsei Chuo Hospital   (Japan)

Author keywords

Aggresome; Autophagy; Breast cancer; ER stress; HDAC6; Proteasome

Indexed keywords

ALPHA TUBULIN; BIM PROTEIN; BORTEZOMIB; CLARITHROMYCIN; DEATH RECEPTOR 5; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; TUBACIN; VORINOSTAT;

ACETYLATION; AGGRESOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST METASTASIS; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; EMBRYO; ENDOPLASMIC RETICULUM STRESS; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

AGGRESOME; AUTOPHAGY; BREAST CANCER; ER-STRESS; HDAC6; PROTEASOME;

ANILIDES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CLARITHROMYCIN; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; INCLUSION BODIES; INTRACELLULAR SPACE; MICE; PROTEOLYSIS; PYRAZINES; TRANSCRIPTION FACTOR CHOP;

MURINAE;

EID: 84880512254     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.032     Document Type: Article

References (29)

1. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
2. Verfaillie T., Salazar M., Velasco G., Agostinis P. Linking ER stress to autophagy: potential implications for cancer therapy. Int. J. Cell Biol. 2010, 930509.
3. Mizushima N., Levine B. Autophagy in mammalian development and differentiation. Nat. Cell Biol. 2010, 12:823-830.
4. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol. 2011, 8:528-539.
5. Kirkin V., McEwan D.G., Novak I., Dikic I. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
6. Korolchuk V.I., Menzies F.M., Rubinsztein D.C. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010, 584:1393-1398.
7. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 2011, 13:184-190.
8. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115:727-738.
9. Rodriguez-Gonzalez A., Lin T., Ikeda A.K., Simms-Waldrip T., Fu C., Sakamoto K.M. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 2008, 68:2557-2560.
10. Simms-Waldrip T., Rodriguez-Gonzalez A., Lin T., Ikeda A.K., Fu C., Sakamoto K.M. The aggresome pathway as a target for therapy in hematologic malignancies. Mol. Genet. Metab. 2008, 94:283-286.
11. Komatsu S., Miyazawa K., Moriya S., Takase A., Naito M., Inazu M., Kohno N., Itoh M., Tomoda A. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. Int. J. Oncol. 2012, 40:1029-1039.
12. Moriya S., Che X.F., Komatsu S., Abe A., Kawaguchi T., Gotoh A., Inazu M., Tomoda A., Miyazawa K. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Int. J. Oncol. 2013, 42:1541-1550.
13. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., Frankel S.R., Chen C., Ricker J.L., Arduino J.M., Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 2007, 25:3109-3115.
14. Namdar M., Perez G., Ngo L., Marks P.A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl. Acad. Sci. USA 2010, 107:20003-20008.
15. Ramaswamy B., Fiskus W., Cohen B., Pellegrino C., Hershman D.L., Chuang E., Luu T., Somlo G., Goetz M., Swaby R., Shapiro C.L., Stearns V., Christos P., Espinoza-Delgado I., Bhalla K., Sparano J.A. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res. Treat. 2012, 132:1063-1072.
16. Aldana-Masangkay G.I., Rodriguez-Gonzalez A., Lin T., Ikeda A.K., Hsieh Y.T., Kim Y.M., Lomenick B., Okemoto K., Landaw E.M., Wang D., Mazitschek R., Bradne J.E., Sakamoto K.M. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk. Lymphoma 2011, 52:1544-1555.
17. Kawaguchi T., Miyazawa K., Moriya S., Ohtomo T., Che X.F., Naito M., Itoh M., Tomoda A. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int. J. Oncol. 2011, 38:643-654.
18. Hoang B., Benavides A., Shi Y., Frost P., Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther. 2009, 8:1974-1984.
19. Nakamura M., Kikukawa Y., Takeya M., Mitsuya H., Hata H. Clarithromycin attenuates autophagy in myeloma cells. Int. J. Oncol. 2010, 37:815-820.
20. Renna M., Schaffner C., Brown K. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Invest. 2011, 121:3554-3563.
21. Haggarty S.J., Koeller K.M., Wong J.C., Grozinge C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003, 100:4389-4394.
22. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., Cleveland J.L., Giles F.J., McConkey D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112:2917-2926.
23. Zinszner H., Kuroda M.M., Wang X., Batchvarova N., Lightfoot R.T., Remotti H. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998, 12:982-995.
24. Oyadomari S., Koizumi A., Takeda K., Gotoh T., Akira S., Arak E., Mori M. Targeted disruption of the chop gene delays endoplasmic reticulum stress-mediated diabetes. J. Clin. Invest. 2002, 109:525-532.
25. Silva R.M., Ries V., Oo T.F., Yarygina O., Jackson-Lewis V. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 2005, 95:974-986.
26. Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992, 6:439-453.
27. Giannini G., Cabri W., Fattorusso C., Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem. 2012, 4:1439-1460.
28. Haakenson J., Zhang X. HDAC6 and ovarian cancer. Int. J. Mol. Sci. 2013, 14:9514-9535.
29. Li G., Jiang H., Chang M., Xie H., Hu L. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J. Neurol. Sci. 2011, 304:1-8.